LifeStance Health Group (LFST) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LifeStance Health Group in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LFST shares.
View LFST analyst ratings or view top-rated stocks.

6 brokers have issued 1-year price targets for LifeStance Health Group's shares. Their LFST share price forecasts range from $7.25 to $9.00. On average, they expect the company's stock price to reach $8.04 in the next twelve months. This suggests that the stock has a possible downside of 5.6%.
View analysts price targets for LFST or view top-rated stocks among Wall Street analysts.

LifeStance Health Group's stock was trading at $4.94 at the beginning of 2023. Since then, LFST stock has increased by 72.5% and is now trading at $8.52.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our LFST earnings forecast.

LifeStance Health Group, Inc. (NASDAQ:LFST) announced its earnings results on Wednesday, May, 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. The company earned $252.59 million during the quarter, compared to the consensus estimate of $246.04 million. LifeStance Health Group had a negative net margin of 20.63% and a negative trailing twelve-month return on equity of 12.32%.

ETFs with the largest weight of LifeStance Health Group (NASDAQ:LFST) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), SPDR S&P Health Care Services ETF (XHS), First Trust Small Cap Growth AlphaDEX Fund (FYC), iShares U.S. Healthcare Providers ETF (IHF).Fidelity New Millennium ETF (FMIL),

LifeStance Health Group issued an update on its second quarter 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250.00 million-$260.00 million, compared to the consensus revenue estimate of $250.46 million.

(LFST) raised $640 million in an initial public offering on Thursday, June 10th 2021. The company issued 40,000,000 shares at $15.00-$17.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan, Jefferies, TPG Capital BD LLC, UBS Investment Bank and William Blair served as the underwriters for the IPO and Capital One Securities, AmeriVet, Drexel Hamilton, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

LifeStance Health Group trades on the NASDAQ under the ticker symbol "LFST."

LifeStance Health Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (6.85%), BlackRock Inc. (1.38%), Principal Financial Group Inc. (0.98%), Geode Capital Management LLC (0.49%), State Street Corp (0.39%) and O Brien Wealth Partners LLC (0.22%). Insiders that own company stock include Anisha Patel-Dunn, Gwen H Booth, Jeffrey Crisan, Jesse Michael Bruff, Kenneth T Mills, Kevin Michael Mullins, Michael K Lester, Silversmith Partners I Gp, Llc, Summit Partners Growth Equity and Warren Gouk.
View institutional ownership trends.

Shares of LFST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LFST stock can currently be purchased for approximately $8.52.

LifeStance Health Group (NASDAQ:LFST) has a market capitalization of $3.21 billion and generates $859.54 million in revenue each year. The company earns $-215,560,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

The company employs 7,830 workers across the globe.

The official website for the company is www.lifestance.com. The company can be reached via phone at 602-767-2100.